Ultimately, using differential gene expression (DGE) analysis, immunohistochemistry (IHC) profiling of original tumor samples, and knock‐out (KO) experiments, our work identifies galectin‐1 (GAL1, LGALS1) as an important immunomodulating target that affects tumor growth. Here, LGALS1 is linked to neoplasm.